- Home
- NXN vs RNTX Comparison
NXN vs RNTX Comparison
Compare NXN & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXN
- RNTX
- Stock Information
- Founded
- NXN 1992
- RNTX 2001
- Country
- NXN United States
- RNTX United States
- Employees
- NXN N/A
- RNTX N/A
- Industry
- NXN Trusts Except Educational Religious and Charitable
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NXN Finance
- RNTX Health Care
- Exchange
- NXN Nasdaq
- RNTX Nasdaq
- Market Cap
- NXN 45.3M
- RNTX 40.3M
- IPO Year
- NXN N/A
- RNTX N/A
- Fundamental
- Price
- NXN $11.56
- RNTX $1.45
- Analyst Decision
- NXN
- RNTX
- Analyst Count
- NXN 0
- RNTX 0
- Target Price
- NXN N/A
- RNTX N/A
- AVG Volume (30 Days)
- NXN 9.7K
- RNTX 31.9K
- Earning Date
- NXN 01-01-0001
- RNTX 08-13-2025
- Dividend Yield
- NXN 4.23%
- RNTX N/A
- EPS Growth
- NXN N/A
- RNTX N/A
- EPS
- NXN 0.24
- RNTX N/A
- Revenue
- NXN N/A
- RNTX N/A
- Revenue This Year
- NXN N/A
- RNTX N/A
- Revenue Next Year
- NXN N/A
- RNTX N/A
- P/E Ratio
- NXN $48.42
- RNTX N/A
- Revenue Growth
- NXN N/A
- RNTX N/A
- 52 Week Low
- NXN $10.64
- RNTX $1.33
- 52 Week High
- NXN $12.45
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- NXN 53.45
- RNTX N/A
- Support Level
- NXN $11.53
- RNTX N/A
- Resistance Level
- NXN $11.68
- RNTX N/A
- Average True Range (ATR)
- NXN 0.13
- RNTX 0.00
- MACD
- NXN 0.02
- RNTX 0.00
- Stochastic Oscillator
- NXN 49.23
- RNTX 0.00
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.